HIV Vaccine Work Awaits Next STEP In Merck Analysis; Failure Aids Biomarker
Executive Summary
Plans for PAVE 100, the National Institute on Allergy and Infectious Diseases' Phase IIb HIV vaccine study, remain on hold until the next wave of Merck's STEP data - also expected to aid preclinical vaccine development - is released, researchers say
You may also be interested in...
Infectious Diseases Space Wide Open For Partnering Beyond Hep C, Conference Finds
The recent spotlight on hepatitis C doesn't mean that's the only hot area in infectious diseases for deals.
Biotech Takes Electrifying Approach To Developing An HIV Vaccine
In the tumultuous quest to create an effective HIV vaccine, an approach that combines a DNA vaccine with a jolt of electricity looks to be a promising candidate in monkeys, but more data is needed in humans before breaking out the champagne, researchers say
Biotech Takes Electrifying Approach To Developing An HIV Vaccine
In the tumultuous quest to create an effective HIV vaccine, an approach that combines a DNA vaccine with a jolt of electricity looks to be a promising candidate in monkeys, but more data is needed in humans before breaking out the champagne, researchers say